Vonoprazan-amoxicillin dual therapy vs. proton pump inhibitor based dual therapy for Helicobacter pylori eradication: a meta-analysis.

ABSTRACT:

Background and objective

In recent years, the use of high-dose dual therapy based on PPI and amoxicillin (PPI-HDDT) has shown satisfactory efficacy in eradicating Helicobacter pylori (H. pylori) as a first-line treatment. Vonoprazan (VPZ), a new potassium-competitive acid blocker, exhibits rapid, potent, and enduring acid inhibitory effects in comparison to PPI. However, to date, evidence comparing VPZ-based HDDT (VPZ-HDDT) with PPI-HDDT for eradication of H. pylori remains limited. This meta-analysis aimed to systematically evaluate the effect of the two regimens for first-line H. pylori eradication.

Methods

This meta-analysis searched PubMed, Embase, Cochrane Library, and Web of Science (from inception to October 1, 2025) for randomized controll

SUBMITTER: Lv Y 

PROVIDER: S-EPMC12847323 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature